Autolus Aucatzyl phase 1 maintains SLE responses with longer follow up

Autolus announced that follow-up data from the ongoing phase 1 (CARLYSLE) dose confirmation trial of Aucatzyl (obe-cel, CD19 CAR-T) in severe refractory systemic lupus erythematosus (srSLE), will be presented during a poster session at the American College of Rheumatology Convergence 2025. The updated results demonstrate durability of outcomes observed in the initial readout (presented April 2025) over a longer follow up period as evidenced by the absence of new disease activity, no other lupus directed therapy required, and all patients achieving steroid tapering (=5mg/day). Autolus is well positioned with a pivotal trial in lupus nephritis planned to begin before YE25 in the B-cell agent/calcineurin inhibitor refractory setting, where there are no options and the regulatory success bar is a 40% CRR. $ 10 TP and BUY maintained.